Keyword: Obsidian Therapeutics
Gilman to be full-time CEO of Arrakis, while Wotton takes over Obsidian; ex-GSK immunology chief to lead Kintai Therapeutics; and Insys swaps CEOs.
The appointment gives Obsidian a full-time CEO following a period in which Michael Gilman helmed the biotech while also running Arrakis Therapeutics.
Celgene ended the week by expanding its CAR-T toolkit via a deal with Obsidian and placing an $80 million bet on Kyn.
AZ research exec Johnson jumps to Goldfinch, Human Longevity undergoes C-suite earthquake, Biogen poaches Takeda exec as CIO.
Michael Gilman retired when Padlock Therapeutics was bought out, but now he’s back to helm a company promising to transform cell and gene therapies.